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Abstract
Background: One aspect of brain death is cardiovascular deregulation because asystole invariably occurs shortly after its
diagnosis. A suitable neural substrate for mechanistic delineation of this aspect of brain death resides in the rostral
ventrolateral medulla (RVLM). RVLM is the origin of a life-and-death signal that our laboratory detected from blood pressure
of comatose patients that disappears before brain death ensues. At the same time, transcriptional upregulation of heme
oxygenase-1 in RVLM by hypoxia-inducible factor-1a (HIF-1a) plays a pro-life role in experimental brain death, and HIF-1a is
subject to sumoylation activated by transient cerebral ischemia. It follows that sumoylation of HIF-1a in RVLM in response to
hypoxia may play a modulatory role on brain stem cardiovascular regulation during experimental brain death.
Methodology/Principal Findings: A clinically relevant animal model that employed mevinphos as the experimental insult in
Sprague-Dawley rat was used. Biochemical changes in RVLM during distinct phenotypes in systemic arterial pressure
spectrum that reflect maintained or defunct brain stem cardiovascular regulation were studied. Western blot analysis, EMSA,
ELISA, confocal microscopy and immunoprecipitation demonstrated that drastic tissue hypoxia, elevated levels of proteins
conjugated by small ubiquitin-related modifier-1 (SUMO-1), Ubc9 (the only known conjugating enzyme for the sumoylation
pathway) or HIF-1a, augmented sumoylation of HIF-1a, nucleus-bound translocation and enhanced transcriptional activity
of HIF-1a in RVLM neurons took place preferentially during the pro-life phase of experimental brain death. Furthermore,
loss-of-function manipulations by immunoneutralization of SUMO-1, Ubc9 or HIF-1a in RVLM blunted the upregulated nitric
oxide synthase I/protein kinase G signaling cascade, which sustains the brain stem cardiovascular regulatory machinery
during the pro-life phase.
Conclusions/Significance: We conclude that sumoylation of HIF-1a in RVLM ameliorates brain stem cardiovascular
regulatory failure during experimental brain death via upregulation of nitric oxide synthase I/protein kinase G signaling. This
information should offer new therapeutic initiatives against this fatal eventuality.
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Introduction
As much as brain death is currently the legal definition of death
in the United States [1], European Union [2] or Taiwan [3] and is
of paramount clinical importance, its cellular and molecular
underpinning remains relatively unsettled. Despite the complexity
of brain death, two clinical observations suggest that mechanistic
delineation of permanent impairment of the brain stem cardio-
vascular regulatory machinery associated with this fatal phenom-
enon may shed light on its underlying mechanisms. First, asystole
invariably takes place within hours or days after the diagnosis of
brain death [4]. Second, a unique clinical phenotype exists in the
low-frequency (LF) component (0.04–0.15 Hz in human) of the
systemic arterial pressure (SAP) spectrum, which reflects the status
of brain stem cardiovascular regulation. The power density of the
LF component undergoes a dramatic reduction or loss before
brain death ensues in comatose patients [5–7]. That this life-and-
death signal originates from the rostral ventrolateral medulla
(RVLM) [8], which is known classically for its role in tonic
maintenance of vasomotor tone and SAP [9], allows this brain
stem site to be a suitable neural substrate for mechanistic
assessment of the brain stem cardiovascular regulatory functions
associated with brain death [10].
In an animal model that employs mevinphos (3-[dimethox-
yphosphinyl-oxyl]-2-butenoic acid methyl ester; Mev) as the
experimental insult [10–12], our laboratory found previously that
on systemic administration, this organophosphate pesticide acts
directly on RVLM to elicit an augmentation followed by a
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temporal pattern resembles that exhibited during the progression
towards brain death by patients died of organophosphate
poisoning [6], they are designated respectively the pro-life and
pro-death phase in this model of brain death [10]. We further
demonstrated that nitric oxide (NO) generated by NO synthase I
(NOS I) in RVLM, followed by activation of the soluble guanylyl
cyclase/cGMP/ protein kinase G (PKG) cascade, is responsible
for the pro-life phase; peroxynitrite formed by a reaction between
NOS II-derived NO and superoxide anion underlies the pro-
death phase [13,14].
That Mev elicits hypoxia in RVLM [15] and that both NOS I
[17,18] and NOS II [19,20] are hypoxia responsive gene
products offer an important clue in our continual search for the
cellular and molecular mechanisms that underlie brain death.
Because of the reduction in the amount of oxygen that reaches
brain tissues, hypoxia in brain tissue may trigger a series of
adaptive responses in neurons. In this regard, the transcription
factor hypoxia-inducible factor 1 (HIF-1) operates as a master
regulator of cellular responses to hypoxia via activation of a
multitude of oxygen-sensitive gene products [21–24]. We
demonstrated recently [25] that one of the hypoxia responsive
gene products upregulated transcriptionally by HIF-1a [26] in
RVLM is heme oxygenase-1, which plays a pro-life role in
experimental brain death by sustaining central cardiovascular
regulatory function via activation of heat shock protein 70 [27]. A
new system of post-translational protein modification that is also
activated by transient cerebral ischemia [28,29] or hypoxia [30],
in addition to phosphorylation and ubiquitin conjugation, is
massive protein conjugation by the small ubiquitin-like modifier
(SUMO). Of note is that HIF-1a is among the many transcription
factors that are sumoylated [31]. Acute hypoxia induces
expression of SUMO-1 [32], although the effects of sumoylation
of HIF-1a on its stability and transcriptional activity are
controversial [33–36]. It follows that sumoylation of HIF-1a in
RVLM in response to hypoxia may play a modulatory role on
brain stem cardiovascular regulation during experimental brain
death.
The present study assessed the hypothesis that sumoylation of
HIF-1a in RVLM participates in brain stem cardiovascular
regulation during brain death by interacting with NOS I/PKG or
NOS II/peroxynitrite signaling pathway. We demonstrated that
sumoylation of HIF-1a in RVLM plays a preferential pro-life role
by ameliorating cardiovascular regulatory failure during brain
death via selective upregulation of NOS I/PKG signaling cascade.
Results
Biphasic cardiovascular responses in experimental brain
death
Figure 1 shows that microinjection bilaterally of Mev (10 nmol)
into RVLM in animals pretreated with vehicle elicited a
progressive hypotension that became significant 100 min after
application, accompanied by indiscernible alterations in heart rate
(HR). Concurrent changes in power density of the LF component
of SAP signals revealed two distinct phases of Mev-induced
cardiovascular responses. The pro-life Phase I entailed a
significantly augmented LF power that endured 80–100 min.
The pro-death Phase II, which lasted the remainder of our 180-
min observation period, exhibited further and significant reduction
in the power density of this spectral component to below baseline
to reflect failure of brain stem cardiovascular regulatory functions
that precedes brain death [10].
Sumoylation of proteins in RVLM ameliorates failure of
brain stem cardiovascular regulation associated with
experimental brain death
The most fundamental premise for the present study is that
sumoylation of proteins in RVLM is causally involved in brain
stem cardiovascular regulation during brain death. Our first series
of experiments employed loss-of-function by immunoneutraliza-
tion to establish this premise. Figure 1 shows that compared to
normal rabbit or mouse serum, pretreatment with microinjection
bilaterally into RVLM of an antiserum (1:20) against SUMO-1 or
Ubc9, the only known conjugating enzyme for the sumoylation
pathway [37,38] 30 min before local application of Mev
(10 nmol), significantly and selectively enhanced the progressive
hypotension and reduced the increase in power density of LF
component of SAP signals during Phase I Mev intoxication,
without affecting HR. In addition, the hypotension and reduced
LF power already exhibited during Phase II were significantly
potentiated.
Preferential augmentation of protein sumoylation in
RVLM during the pro-life phase
We next evaluated the logical possibility that the augmentation
of sumoylated proteins in RVLM underpins its ameliorating effect
on Mev-elicited central cardiovascular regulatory dysfunction,
noting that acute hypoxia induces expression of SUMO-1 [32]. In
this particular set of experiments, Mev was given intravenously
because the dimension of this neural substrate does not allow for
simultaneous placement of the glass micropipette used for
microinjection and the probe used for sensing tissue oxygen and
blood flow. Our laboratory demonstrated previously [16] that
systemic administration of Mev induces cardiovascular responses
by acting on RVLM. Given at an i.v. dose of 640 mgk g
21, the
elicited changes in SAP, HR and LF power were compatible both
in magnitude and time-course with those induced by microinjec-
tion of Mev (10 nmol) directly to RVLM. Figure 2A shows that the
tissue oxygen tension in RVLM underwent, after a short latency, a
drastic drop by 1265 mmHg (n=7) that lasted 8–10 min after i.v.
administration of Mev. This was followed by a sustained hypoxia
at 462 mmHg (n=7) below baseline over the remainder of our
180-min observation period. Intriguingly, the local blood flow
responded with an increase that mirrored the abrupt hypoxia,
followed by a sustained reduction of approximately 550660 blood
perfusion units (BPU) (n=7).
Western blot analysis (Figure 2B) revealed a significant
augmentation of proteins that were conjugated to SUMO-1 in
both cytosolic and nuclear fractions of extracts from ventrolateral
medulla during early Phase I when the drastic drop in tissue
oxygen level in RVLM took place. This increase sustained
throughout Phase I, and returned to baseline during Phase II
Mev intoxication. Ubc9 exhibited similar temporal expression
pattern (Figure 2B). On the other hand, the level of proteins
conjugated by SUMO-1 or expression of Ubc9 in ventrolateral
medulla of animals that received artificial cerebrospinal fluid
(aCSF) was comparable to sham controls (Figure 2B and 2C).
Double immunofluorescence staining coupled with laser scanning
confocal microscopy revealed that the results on SUMO-1
demonstrated in our biochemical analyses on protein extracts
from ventrolateral medulla indeed took place at the neuronal level.
Against a clearly defined nucleus and nucleolus in cells stained
positively with the neuronal marker, neuron-specific nuclear
protein (NeuN), there was an increased presence of SUMO-1-
immunoreactivity in the cytoplasm and nucleus of RVLM neurons
during early and late Phase I when compared with sham control or
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(Figure 2D).
Activation of HIF-1a in RVLM also ameliorates failure of
brain stem cardiovascular regulation associated with
experimental brain death
Our third series of experiments investigated whether HIF-1a,
which is potently activated by hypoxia [22–24], also participates in
brain stem cardiovascular regulation during experimental brain
death. Western blot analysis (Figure 3A) on total proteins extracted
from ventrolateral medulla revealed that whereas HIF-1b or HIF-
2a expression remained constant, HIF-1a level was significantly
elevated during early Phase I when drastic drop in tissue oxygen
level in RVLM took place. This augmented HIF-1a expression
sustained throughout Phase I, and returned to baseline during
Phase II Mev intoxication. HIF-1a, HIF-1b or HIF-2a expression
in ventrolateral medulla of animals that received aCSF was
comparable to sham controls (Figure 3A). Detailed immunoblot
analysis (Figure 3B) further established a significant elevation of
HIF-1a in both the nuclear and cytosolic fractions of proteins
extracted from ventrolateral medulla during Phase I Mev
intoxication. On the other hand, the primarily nuclear presence
of HIF-1b subunit (Figure 3B) or cytosolic presence of HIF-2a
(data not shown) remained constant. Again, double immunoflu-
orescence staining coupled with laser scanning confocal micros-
copy revealed that immunoreactivity of HIF-1a (Figure 3C) was
identified primarily in the cytoplasm and HIF-1b in the nucleus of
RVLM neurons in sham-control animals. During early and late
Phase I, the abundant presence of HIF-1a immunoreactivity in the
nucleus of RVLM neurons (Figure 3C) was accompanied by an
augmented amount in the cytoplasm, which subsided during Phase
II. On the other hand, there was minimal alteration in the
preferential presence of HIF-1b immunoreactivity in the nucleus
(Figure 3C) of RVLM neurons during both phases of Mev
intoxication.
Figure 1. Sumoylation of proteins in RVLM ameliorates failure of central cardiovascular regulation in Mev intoxication model of
brain death. Temporal changes in mean systemic arterial pressure (MSAP), heart rate (HR) or power density of the low-frequency (LF) component of
SAP signals in rats that received pretreatment by microinjection bilaterally into RVLM of an anti-SUMO-1 or anti-Ubc9 antiserum (1:20), normal rabbit
serum (NRS,1:20; vehicle for anti-SUMO antiserum) or normal mouse serum (NMS, 1:20; vehicle for anti-Ubc9 antiserum), 30 min before local
application (at arrow) of artificial cerebrospinal fluid (aCSF) or mevinphos (Mev; 10 nmol) to the bilateral RVLM. Values are mean 6 SEM, n=5–7
animals per experimental group. *P,0.05 versus NRS+aCSF or NMS+aCSF group, and
+P,0.05 versus NRS+Mev or NMS+Mev group at corresponding
time-points in the post hoc Scheffe ´ multiple-range test. B, baseline.
doi:10.1371/journal.pone.0017375.g001
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scription activity via the formation of heterodimer between HIF-
1b and HIF-1a or HIF-2a in the nucleus [39–41]. Results from
electrophoresis mobility shift assay (EMSA) (Figure 4A and 4B)
demonstrated a significant increase in the association of HIF-1
with its consensus DNA oligonucleotide in nuclear extracts from
ventrolateral medulla during the pro-life Phase I, which returned
during the pro-death Phase II to levels exhibited by sham or aCSF
controls. We confirmed that this association was not due to non-
specific binding when a competitive assay using unlabeled
oligonucleotide probe resulted in discernible disappearance of
HIF-1 DNA binding (Figure 4A and 4B). Supershift experiments
(Figure 4B) revealed that an antiserum against HIF-1a, but not
HIF-1b or HIF-2a (data not shown), retarded the migration of
proteins that interacted with the double-stranded HIF-1 oligonu-
cleotide. Immunoblot analysis of proteins immunoprecipitated by
an anti-HIF-1b antiserum from the nuclear fraction of ventrolat-
eral medullary samples additionally confirmed a preferential
augmentation in the complex formed between HIF-1b and HIF-
1a during the pro-life phase of Mev intoxication (Figure 4C). On
the other hand, the association between HIF-1b and HIF-2a
during both phases was unaffected (Figure 4C). As a control
(Figure 4D), minimal association between HIF-1b and HIF-1a or
HIF-2a was detected from the cytosolic fraction during both
phases. The activation of HIF-1a in RVLM is causally involved in
central cardiovascular regulation in our model of brain death
(Figure 5). Immunoneutralization of HIF-1a or HIF-1b in RVLM
significantly enhanced the progressive hypotension and antago-
nized the increase in power density of LF component of SAP
signals during Phase I Mev intoxication, without affecting HR.
Furthermore, the hypotension and reduced LF power already
exhibited during Phase II was again significantly augmented. On
the other hand, pretreatment with the same dose of anti-HIF-2a
antiserum (Figure 5) was ineffective against the phasic cardiovas-
cular responses induced by Mev.
Preferential sumoylation of HIF-1a in RVLM during the
pro-life phase
As a well-documented target for SUMO-1 [33–36], our fourth
series of experiments evaluated whether augmentation of sumoyla-
tion of HIF-1a is causally related to its enhanced stability or
transcriptional activity in RVLM during the pro-life phase. Results
from immunoblot analysis of HIF-1a in proteins immunoprecip-
itated by SUMO-1 showed a preferential increase during Phase I
Mev intoxication in the association of SUMO-1 and HIF-1a in
both the nuclear and cytosolic fractions from ventrolateral medulla
(Figure 6A). Comparable results were obtained from immunoblot
analysis of SUMO-1 from proteins immunoprecipitated by HIF-
1a (Figure 6B). Furthermore, microinjection bilaterally of an anti-
SUMO-1 or anti-Ubc9 antiserum (1:20) in RVLM significantly
blunted the preferentially augmented HIF-1a expression
(Figure 6C) and antagonized the heightened transcription activity
of HIF-1a in whole cell lysate of ventrolateral medulla during this
pro-life phase (Figure 6D).
Activation of HIF-1 leads to phasic upregulation of NOS I/
PKG signaling in RVLM
We demonstrated previously [11–14] that whereas NOS I/
PKG signaling in RVLM is responsible for the pro-life phase,
NOS II/peroxynitrite signaling underlies the pro-death phase of
Mev intoxication. Our final series of experiments assessed whether
the upregulation of HIF-1 may subserve its pro-life role via
modulation of these two signaling pathways. Immunoneutraliza-
tion of HIF-1a or HIF-1b (Figure 7) blunted significantly and
selectively the Mev-induced Phase I increase in NOS I or PKG
protein expression in ventrolateral medulla. None of these
pretreatments affected the progressive increase in NOS II or
nitrotyrosine (marker for peroxynitrite) during both phases of Mev
intoxication. Again, anti-HIF-2a antiserum was ineffective
(Figure 7) against the phasic Mev-induced NOS I, PKG, NOS
II or nitrotyrosine protein expression in ventrolateral medulla.
Discussion
HIF-1 activation plays an important role in tissue preservation as
a response to regional hypoxia [42]. Of the very limited amount of
information available on the functional role of HIF-1 in the brain,
HIF-1a activation in cortical neurons produces rescue proteins in
responsetointermittenthypoxia [43].HIF-1isaheterodimeroftwo
basic helix-loop-helix/PAS proteins, HIF-1a and HIF-1b [40].
HIF-1a is rapidly degraded under normoxic conditions by the
ubiquitin-proteasome system, and HIF-1b is constitutively ex-
pressed in the nucleus and its level is not significantly affected by
oxygen levels [41]. Hypoxia stabilizes HIF-1a, and nucleus-bound
translocation of the stabilized HIF-1a allows for formation of the
HIF-1ab heterodimer that becomes transcriptionally active [39].
Jewell et al. [44] showed that human epithelial carcinoma cell line
HeLaS3 already exhibited nuclear HIF-1a protein induction and
HIF-1 DNA binding after the introduction of hypoxia for less than
2 min, reaching maximal levels one hour after anoxic/hypoxic
exposure. Based on complementary results from Western blot
analysis, EMSA,confocal microscopy and immunoprecipitation, we
demonstrated that the repertoire of cellular events that included
nucleus-bound translocation of HIF-1a, followed by formation of
HIF-1ab heterodimer in RVLM neurons during the pro-life phase
of Mev intoxication exhibited a time-course that paralleled the
elicited drastic hypoxia in RVLM. More importantly, loss-of-
function manipulations in conjunction with monitors of circulatory
events showed that the activated HIF-1a ameliorated brain stem
cardiovascular regulatory failure during the progression towards
experimental brain death. We further found that HIF-2a plays no
part in this process.
Figure 2. Severe hypoxia and preferential augmentation of protein sumoylation in RVLM during the pro-life phase. (A) Representative
continuous tracings showing temporal changes of tissue oxygen concentration (upper panel) or microvascular perfusion (lower panel) in RVLM of rats
that received intravenous administration of Mev (640 mgk g
21, at dashed line) during early Phase I (EMI) and Phases I and II (MI and MII) Mev
intoxication. BPU: blood perfusion unit. (B and C) Illustrative gels or summary of fold changes against sham (S) controls of nuclear or cytosolic proteins
that were conjugated to SUMO-1 (B) or Ubc9 protein expression (C) detected in ventrolateral medulla during Phases EMI, MI and MII Mev intoxication
or in aCSF (V) controls. Since comparable results were obtained from all corresponding time intervals after animals received microinjection of aCSF,
only one set of data is presented in this and subsequent figures for clarity. Values are mean 6 SEM of triplicate analyses on samples pooled from 4–6
animals in each group. *P,0.05 versus aCSF group in the post hoc Scheffe ´ multiple-range analysis. Note numbers on bottom of the gels correspond
to columns in the data summary. (D) Representative laser scanning confocal microscopic images showing cells in RVLM that were immunoreactive to
SUMO-1 (green fluorescence) and additionally stained positively for a neuronal marker, neuron-specific nuclear protein (NeuN; red fluorescence) in
sham controls or during Phases EMI, MI and MII Mev intoxication. These results are typical of 4 animals from each experimental group. Scale bar,
20 mm.
doi:10.1371/journal.pone.0017375.g002
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PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17375A novel contribution of the present study is the identification of
a vital role for sumoylation of HIF-1a in RVLM in ameliorating
brain stem cardiovascular regulatory dysfunction during brain
death. The covalent conjugation of SUMOs to proteins has
received much attention since its discovery [45,46] because the
affected proteins are involved in gene expression, chromatin
structure, signal transduction or maintenance of the genome [31].
Transient global cerebral ischemia induces massive increases in
sumoylation of proteins, including transcription factors [29]. In
particular, hypoxia increases SUMO-1 mRNA and protein levels
in brain, and the induced SUMO-1 co-expresses with HIF-1a in
neurons [32]. However, controversy exists on the cellular sequel of
modulation of HIF-1a through sumoylation. It is generally
contended that sumoylation of transcription factors blocks their
activation [37,47]. Thus, conjugation of SUMO to HIF-1a
decreases its activity [34], and hypoxia-induced sumoylation of
HIF-1a leads to its ubiquitination and degradation [36]. On the
other hand, Bae et al. [33] reported that upregulation of HIF-1a
through SUMO-1 modification at Lys(391)/Lys(477) residues
increases its stability and enhances its transcriptional activity, and
sumoylation of HIF-1a blocks its degradation [29]. Whereas the
present study was not designed to address this controversy,
complementary results from our biochemical and physiological
experiments strongly indicated that elevation in SUMO-1 and
Ubc9 levels that paralleled temporally with hypoxia, followed by
an increase in conjugation between SUMO-1 and HIF-1a, took
place in RVLM preferentially during the pro-life phase. More
importantly, we demonstrated in our model that this enhanced
sumoylation of HIF-1a in RVLM ameliorates the dysfunction of
brain stem cardiovascular regulation associated with brain death.
The return of SUMO-1, Ubc9 or HIF-1a expression in RVLM to
control levels during phase II despite a sustained oxygen level at
462 mmHg below baseline suggests that stronger hypoxic drive is
required to trigger sumoylation of HIF-1a and its transcriptional
activities. Although unrelated directly to brain death, the
engagement of sumoylation in cardiovascular regulation is
reported in a recent study [48]. Sumoylation of phosducin inhibits
postganglionic sympathetic neuron activity and prevents stress-
induced hypertension.
Gill [49] reviewed that SUMO shares structural homology with
ubiquitin, and the machinery that attaches SUMO to substrate
proteins and the enzymes that participate in ubiquitination are
strikingly similar. As such, SUMO may compete with ubiquitin for
the same lysine residues and function essentially as an antiubiqui-
tin [47]. We reason that this modus operandi is at work in RVLM
during brain death, noting that degradation of HIF-1a by the
ubiquitin-proteasome system determines its prevalence [41]. In
support of this notion, we demonstrated a preferential increase of
association between SUMO-1 and HIF-1a in RVLM during the
pro-life phase, and that immunoneutralization of SUMO-1 or
Ubc9 significantly antagonized the augmented expression of HIF-
1a in RVLM and exacerbated the dysfunction of brain stem
cardiovascular regulation. We noted that the level of augmented
HIF-1a detected from proteins immunoprecipitated by SUMO-1
during the pro-life phase (Figure 6A) was not overtly more than the
increase in HIF-1a determined from total protein (Figure 3A). It is
likely that this seeming discrepancy is a demonstration of the
phenomenon of SUMO enigma [31], which stipulates that only a
small proportion of the available substrate protein needs to be
sumoylated to achieve maximal effects.
A well-known hypoxia responsive gene product is NOS II
[19,26]. Melillo et al. [50] showed that a sequence homologous to
a hypoxia-responsive enhancer (NOS II-HRE) is responsible for
activation of nos II gene in murine macrophages. A putative HIF-1
site (CTACGTGCT) in the murine NOS II gene was subsequently
shown to be crucial for hypoxia-induced transcription in
pulmonary artery endothelial cells [51] and cardiomyocytes [52].
Results from our previous studies [11–14] indicated that NOS II/
peroxynitrite signaling in RVLM underlies the significant
dysfunction of cardiovascular regulation seen during the pro-
death phase of brain death. Since immunoneutralization of HIF-
1a or HIF-1b did not significantly affect the progressive
augmentation of NOS II or nitrotyrosine levels in ventrolateral
medulla in our animal model, the participation of HIF-1 as a
cellular signal upstream to NOS II/peroxynitrite pathways is
deemed minimal. Our results did lend credence to the notion that
HIF-1 acts as the upstream cellular signal to NOS I/PKG
pathways. Hypoxia increases NOS I expression that parallels
activation of HIF-1a in piglet ventricular tissues [17]. An increase
in NOS I and HIF-1a expression also occurs in cerebral cortex of
anemic rats [18]. The present study further showed that
immunoneutralization of HIF-1a or HIF-1b blunted the surge of
NOS I or PKG expression during Phase I Mev intoxication.
In conclusion, the present study provided novel demonstration
that enhanced sumoylation and stabilization of HIF-1a in response
to hypoxia in RVLM ameliorates the dysfunction of brain stem
cardiovascular regulation in our Mev intoxication model of brain
death via augmented expression selectively of the pro-life NOS I/
PKG signaling cascade. It is generally contended that hypoxia
serves as the culprit for many abnormal brain functions.
Nonetheless, working in conjunction with a neural substrate
whose neuronal activity is reflected in the waxing and waning of
the life-and-death signal, it is intriguing that our results
demonstrated that enhanced protein sumoylation in response to
hypoxia in RVLM in fact ameliorates brain stem cardiovascular
regulatory failure associated with experimental brain death. This
information, along with the signaling cascades identified in the
present study, should provide further mechanistic insights into the
etiology of brain death and offer new directions for the
development of therapeutic strategy against this fatal eventuality
aiming at preventing brain stem cardiovascular regulatory failure.
Materials and Methods
Ethics Statement
All experimental procedures carried out in this study have been
approved by the Laboratory Animal Committee of the Kaohsiung
Chang Gung Memorial Hospital (CGMH97006), and were in
compliance with the guidelines for animal care set forth by this
Committee.
Figure 3. Preferential nucleus-bound translocation of HIF-1a in RVLM during the pro-life phase. (A and B) Illustrative gels or summary of
fold changes against sham (S) controls in ratio of total protein of HIF-1a, HIF-1b or HIF-2a relative to b-actin protein (A), or nuclear or cytosolic
content of HIF-1a or HIF-1b protein (B) detected in ventrolateral medulla during Phases EMI, MI and MII Mev intoxication or in aCSF (V) controls.
Values are mean 6 SEM of triplicate analyses on samples pooled from 4–6 animals in each group. *P,0.05 versus aCSF group in the post hoc Scheffe ´
multiple-range analysis. Note numbers on top of the gels correspond to columns in the data summary. (C) Representative laser scanning confocal
microscopic images showing cells in RVLM that were immunoreactive to NeuN (green fluorescence) and additionally stained positively for HIF-1a or
HIF-1b subunit (yellow fluorescence or colocalization of red and green fluorescence) in sham controls or during Phases EMI, MI and MII Mev
intoxication. These results are typical of 4 animals from each experimental group. Scale bar, 8 mm.
doi:10.1371/journal.pone.0017375.g003
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PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17375Figure 4. Preferential augmentation of HIF-1a transcription activity in RVLM during the pro-life phase. (A and B) Illustrative gels
depicting HIF-1 DNA binding in nuclear extracts from ventrolateral medulla of sham or aCSF controls, or during Mev intoxication. Results from
supershift analysis illustrated in (B) were obtained from nuclear extracts from ventrolateral medulla collected during Phase I that was preincubated
with antiserum against HIF-1a or HIF-1b. Competitive assay using unlabeled HIF oligonucleotide served as the negative control (Cold). These results
are typical of 4 animals from each experimental group. (C and D) Illustrative gels or summary of fold changes against sham (S) controls of HIF-1a or
HIF-2a from proteins immunoprecipitated by anti-HIF-1b antiserum in the nuclear (C) or cytosolic (D) fraction of samples collected from ventrolateral
medulla of sham (S) or aCSF (V) controls or during Phases MI and MII Mev intoxication. Values are mean 6 SEM of triplicate analyses on samples
pooled from 4–6 animals in each group. *P,0.05 versus aCSF group in the post hoc Scheffe ´ multiple-range test.
doi:10.1371/journal.pone.0017375.g004
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AdultmaleSprague-Dawley rats(264 to 345 g, n=285) purchased
from the Experimental Animal Center of the National Science
Council, Taiwan were used. Rats received preparatory surgery under
an induction dose of pentobarbital sodium (50 mg kg
21, i.p.). During
the experiment, animals received continuous intravenous infusion of
propofol (20–25 mg kg
21 h
21; Zeneca, Macclesfield, UK), which
provided satisfactory anesthetic maintenance while preserving the
capacity of central cardiovascular regulation [53]. They were allowed
to breathe spontaneously with room air, and body temperature was
maintained at 37uCb yah e a t i n gp a d .
Mev intoxication model of brain death
SAP signals recorded from the femoral artery were subject to
simultaneous on-line and real-time power spectral analysis [11–
14,25,27]. We were particularly interested in the LF (0.25–0.8 Hz)
component of the SAP spectrum because it takes origin from
RVLM [8] and the waxing and waning of the LF power reflects
the prevalence of the pro-life and pro-death phases during the
progression towards brain death in patients who succumbed to
organophosphate poisoning [10]. HR was derived instantaneously
from SAP signals. Since Mev induces comparable cardiovascular
responses when given systemically or directly to RVLM [16], we
routinely microinjected Mev bilaterally into RVLM to elicit site-
specific effects [11–14,25,27]. The only exception was when Mev
was given intravenously in conjunction with evaluation of tissue
hypoxia in RVLM. Temporal changes in pulsatile SAP, mean
SAP (MSAP), HR and power density of the LF component were
routinely followed for 180 min after the administration of Mev, in
an on-line and real-time manner.
Microinjection of test agents
Microinjection bilaterally of test agents into RVLM, each at a
volume of 50 nl, was carried out stereotaxically and sequentially
[11–14,25,27] via a glass micropipette connected to a 0.5-ml
Hamilton microsyringe (Reno, NV). The coordinates used were:
4.5–5 mm posterior to lambda, 1.8–2.1 mm lateral to midline,
and 8.1–8.4 mm below the dorsal surface of cerebellum. Test
Figure 5. Activation of HIF-1a in RVLM ameliorates failure of central cardiovascular regulation associated with experimental brain
death. Temporal changes in MSAP, HR or power density of LF component of SAP signals in rats that received pretreatment by microinjection
bilaterally into RVLM of NRS (1:20), anti-HIF-1a, HIF-1b or HIF-2a antiserum (1:20), 30 min before local application (at arrow) of aCSF or Mev (10 nmol)
to the bilateral RVLM. Values are mean 6 SEM, n=5–7 animals per experimental group. *P,0.05 versus NRS+aCSF group, and
+P,0.05 versus
NRS+Mev group at corresponding time-points in the post hoc Scheffe ´ multiple-range test. B, baseline.
doi:10.1371/journal.pone.0017375.g005
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Corporation, Tainan, Taiwan) and aCSF that served as the
vehicle control. A rabbit polyclonal antiserum against HIF-1a
(Novus Biologicals, Littleton, CO), HIF-1b (Lifespan Biosciences,
Seattle, WA), HIF-2a (Novus) or SUMO-1 (Cell Signaling,
Danvers, MA); or a mouse polyclonal antiserum against Ubc9
(BD, San Jose, CA) was used to effect immunoneutralization. As in
previous studies [11,12], 0.02% Triton X-100 (Sigma-Aldrich, St.
Louis, MO) was added to facilitate transport of the antiserum
across the cell membrane of RVLM neurons. Microinjection of
normal rabbit serum (NRS; Sigma-Aldrich) or normal mouse
serum (NMS; Sigma-Aldrich) plus 0.02% Triton X-100 served as
Figure 6. Preferential sumoylation of HIF-1a in RVLM during the pro-life phase. (A and B) Illustrative gels or summary of fold changes
against sham (S) controls of HIF-1a from proteins immunoprecipitated by anti-SUMO-1 antiserum (A); or SUMO-1 from proteins immunoprecipitated
by anti-HIF-1a antiserum (B) in the nuclear or cytosolic fraction of samples collected from ventrolateral medulla of sham (S) or aCSF (V) controls
during Phases MI and MII Mev intoxication. (C and D) Illustrative gels or summary of fold changes against sham (S) controls in ratio of HIF-1a relative
to b-actin protein in whole cell lysate (C) or transcriptional activity of HIF-1a in nuclear extract measured by an ELISA-based HIF-1 transcription factor
assay kit (D) that detects the amount of HIF-1 binding to an oligonucleotide containing the hypoxia response element sequence from rats that
received pretreatment by microinjection bilaterally into RVLM of an anti-SUMO-1 or anti-Ubc9 antiserum (1:20), NRS (1:20) or NMS (1:20), 30 min
before local application of aCSF or Mev (10 nmol) to the bilateral RVLM. Values are mean 6 SEM of triplicate analyses on samples pooled from 4–6
animals in each group. *P,0.05 versus aCSF, NRS or NMS group in the post hoc Scheffe ´ multiple-range test. Note numbers below (A, B) or on top (C)
of the gels correspond to columns in the data summary.
doi:10.1371/journal.pone.0017375.g006
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phrase ‘‘0.02% Triton X-100’’ is omitted from subsequent
narration. To avoid the confounding effects of drug interactions,
each animal received only one antiserum pretreatment.
Evaluation of tissue hypoxia in RVLM
A combined oxygen/temperature/blood flow probe (Oxford
Optronix, Oxford, UK) stereotaxically positioned into RVLM was
used in experiments that called for simultaneous and continuous
measurement of tissue oxygen tension, temperature, and microvas-
cular perfusion [15]. The dimension of the tip of the probe is
approximately 800 mm. Instantaneous changes in local oxygen
tension, compensated for fluctuations in tissue temperature, were
processed by an OxyLite monitor (Oxford Optronix). Real-time
microvascular red blood cell perfusion in tissue was processed by an
OxyFlo monitor (Oxford Optronix). Laser Doppler signals from the
tissue were recorded in blood perfusion units (BPU), which is a
relative unit defined against a controlled motility standard.
Figure 7. Activation of HIF-1 leads to upregulation of NOS I/PKG signaling in RVLM during the pro-life phase. Illustrative gels or
summary of fold changes against aCSF controls in ratio of nitric oxide synthase I (NOS I), protein kinase G (PKG), NOS II or nitrotyrosine (NT; marker for
peroxynitrite) relative to b-actin protein detected in ventrolateral medulla of rats that received immunoneutralization of HIF-1a, HIF-1b or HIF-2a
subunit in RVLM, 30 min before induction of Mev intoxication. Note that NT is presented as % relative to b-actin because it is below detection limit
(ND) in aCSF controls. Values are mean 6 SEM of triplicate analyses on samples pooled from 4–6 animals per experimental group. *P,0.05 versus
aCSF group and
+P,0.05 versus Mev group in the post hoc Scheffe ´ multiple-range test.
doi:10.1371/journal.pone.0017375.g007
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We routinely collected tissue samples [11–14,25,27] during the
peak of the pro-life and pro-death phase (Mev group) or 30 or
180 min after microinjection of aCSF into RVLM (vehicle group).
The brain was rapidly removed and placed on dry ice, and tissues
from both sides of the ventrolateral medulla, at the level of RVLM
(0.5 to 1.5 mm rostral to the obex) were collected by micropunches
made with a stainless steel bore (1 mm i.d.) and frozen in liquid
nitrogen. Medullary tissues collected from anesthetized animals but
without treatment served as the sham controls. In some experi-
ments, proteins from the nuclear or cytosolic fraction of the samples
were extracted using a commercial kit (Active Motif, Carlsbad, CA).
Total protein or that in the nuclear or cytosolic extracts was
estimated by BCA Protein Assay (Pierce, Rockford, IL).
Protein expression
We employed Western blot analysis [11–14,25,27] to detect
changes in expression of HIF-1a, HIF-1b, HIF-2a, Ubc9, NOS I,
PKG, NOS II or nitrotyrosine (marker for peroxynitrite) protein,
or proteins conjugated by SUMO-1. The primary antiserum used
for HIF-1a, HIF-1b, HIF-2a, SUMO-1 or Ubc9 were the same as
those used for immunoneutralization. The other primary antisera
used included a rabbit polyclonal antiserum against NOS I (Santa
Cruz, Santa Cruz, CA), NOS II (Santa Cruz), PKG (Calbiochem,
San Diego, CA); or a mouse monoclonal antiserum against
nitrotyrosine (Upstate Biotechnology, Lake Placid, NY) or b-actin
(Chemicon, Temecula, CA). The secondary antisera used included
horseradish peroxidase-conjugated donkey anti-rabbit IgG (Ge-
healthcare, Uppsala, Sweden) for HIF-1a, HIF-1b, HIF-2a,
SUMO-1, NOS I, NOS II, PKG; or horseradish peroxidase-
conjugated sheep anti-mouse IgG (Gehealthcare) for Ubc9,
nitrotyrosine or b-actin. The amount of protein was quantified
by the ImageMaster software (Amersham Pharmacia Biotech,
Buckinghamshire, UK), and was expressed as the ratio relative to
b-actin protein. Densitometric values that were not statistically
different from the background were designated below detection
limits.
Transcriptional activity of HIF-1
We measured HIF-1 DNA binding capacity [12] in nuclear
proteins extracted from ventrolateral medulla using EMSA [54].
The 39 end of a double-stranded synthetic oligonucleotide probe
for HIF-1 (59-ACCGGCCCTACGTGCT-GTCTCAC-39 and 39-
TGGCCGGGATGCACGACAGAGTG-59) [54] was labeled
with digoxigenin-11-ddUTP (Roche, Penzberg, Germany). DNA
and protein complexes resolved on 4% polyacrylamide gels by
electrophoresis were detected by chemiluminescence after reacting
with an anti-digoxigenin antiserum. Competitive assay using
unlabeled HIF oligonucleotide served as the negative control. A
rabbit polyclonal antiserum against HIF-1a or HIF-1b (Santa
Cruz) was added to the DNA binding reaction cocktail in
supershift assay to determine the participation of HIF subunits.
The occurrence of nucleus-bound translocation of HIF-1a was
confirmed using Western blot analysis on cytosolic or nuclear
proteins [11,12]. In some experiments, we quantified the
transcription activity of HIF-1a using an ELISA-based HIF-1
transcription factor assay kit (Active Motif, Carlsbad, CA) [27]. In
brief, HIF present in nuclear extract was allowed to bind to an
oligonucleotide containing the hypoxia response element sequence
(59-TACGTGCT-39). After the introduction of an antibody that
recognizes an epitope on HIF-1a that is accessible on DNA
binding, the addition of a secondary horseradish peroxidase-
conjugated antibody provided a sensitive colorimetric readout that
can be determined by spectrophotometry. HIF-1a activity was
quantified by measuring the absorbance at 450 nm using an
ELISA microtiter plate reader (Anthros Labtec, Salzburg, Austria),
and was expressed as fold changes against sham controls.
Immunofluorescence staining and confocal microscopy
We employed double immunofluorescence staining coupled
with laser scanning confocal microscopy [11,12] to detect nucleus-
bound translocation or subcellular localization of HIF-1a, HIF-1b
or SUMO-1 in RVLM neurons labeled with a mouse monoclonal
antiserum against a specific neuron marker, neuron-specific
nuclear protein (NeuN; Chemicon). Secondary antisera (Molecu-
lar Probes, Eugene, OR) used included a goat anti-rabbit IgG
conjugated with Alexa Fluor 568 for HIF-1a or HIF-1b, and a
goat anti-mouse IgG conjugated with Alexa Fluor 488 for NeuN;
or a goat anti-rabbit IgG conjugated with Alexa Fluor 488 for
SUMO-1 and a goat anti-mouse IgG conjugated with Alexa Fluor
568 for NeuN. Tissues similarly processed but omitting primary
antiserum against HIF-1a, HIF-1b or SUMO-1 served as our
negative controls. Immunoreactivity was viewed under a Fluor-
view FV10i laser scanning confocal microscope (Olympus, Tokyo,
Japan).
Immunoprecipitation and immunoblot analysis
We employed immunoprecipitation followed by immunoblot
analysis [11,12] to establish an interaction between HIF-1b and
HIF-1a in nuclear proteins, or between SUMO-1 and HIF-1a in
both cytosolic and nuclear proteins extracted from ventrolateral
medulla. Protein extracts were immunoprecipitated with affinity-
purified goat polyclonal anti-HIF-1b, rabbit polyclonal anti-
SUMO-1 or mouse monoclonal anti-HIF-1a antiserum conjugat-
ed with protein G-agarose beads (Santa Cruz). Western blot
analysis of HIF-1a or HIF-2a from proteins immunoprecipitated
by anti-HIF-1b antiserum, HIF-1a from proteins immunoprecip-
itated by anti-SUMO-1 antiserum, or SUMO-1 from proteins
immunoprecipitated by anti-HIF-1a antiserum was carried out as
described above.
Histology
In some animals that were not used for biochemical analysis, the
brain stem was removed at the end of the physiological experiment
and fixed in 10% formaldehyde-saline solution that contains 30%
sucrose for at least 72 h. Frozen 25-mm sections of the medulla
oblongata stained with neural red were used for histological
verification of the microinjection sites.
Statistical analysis
All values are expressed as mean 6 SEM. The effects of various
treatments on the averaged value of MSAP or HR calculated
every 20 min after administration of test agents or vehicle, the sum
total of power density for LF component in the SAP spectra over
20 min, or the protein expression level in the ventrolateral medulla
during each phase of Mev intoxication, were used for statistical
analysis. One-way or 2-way ANOVA with repeated measures was
used, as appropriate, to assess group means. This was followed by
the Scheffe ´ multiple-range test for post hoc assessment of
individual means. P,0.05 was considered to be statistically
significant.
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